Metaloproteinazy – znaczenie w procesie nowotworzenia, diagnostyce i terapii

• Authors: Jacek Pietrzak , Marek Mirowski

Title variants

EN

Metalloproteinases – importance in cancer development, diagnostics and therapy

• Languages of publication: PL

Abstracts

EN

Metalloproteinases (MMP) are proteolytic enzymes whose activity is determined by the presence of zinc ion in the active site and are a widely distributed family of protease to ensure the preservation of homeostasis in animals. In human body they also play many important functions participating in the process of embryogenesis as well as in the formation of blood cells or bone formation. The main role, as it seemed at the beginning research on this group of enzymes, was to digest the extracellular matrix. However, over the years, it turned out that metalloproteinases are important part in the regulation of cell biology, in particular a tumor cell. Studies have confirmed the participation of metalloproteinases in all stages of the process of carcinogenesis. At the moment, there are numerous reports of available of various MMPs in different tumors. However, two of these MMP–2 and MMP–9 belonging to the gelatinases seem to be the most common. It has been confirmed also that higher levels usually indicate a worse prognosis for the patient. Therefore, they may prove to be a valuable prognostic indication for clinicians. Attention was paid to the potential use of matrix metalloproteinases in targeted therapy. The pharmaceutical industry has long been trying to launch metalloproteinase inhibitors as possible therapeutics in cancer, seeing in them a potential that, however, is limited to the early stages of development. After initial setbacks related primarily to the low selectivity is used at once more modern methods as monoclonal antibodies or liposomal drug delivery system. Thus, giving the possibility of treatment that does not cause so enormous side effects as conventional therapy.

Keywords

EN

cancer; therapy.; cancer diagnostics; carcinogenesis; diagnostyka; nowotworowa; kancerogeneza; metalloproteinases; metaloproteinazy; terapia w chorobie nowotworowej

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2015
• Volume: 42
• Issue: 1
• Pages: 33-48

Contributors

author

Jacek Pietrzak

• Zakład Biochemii Farmaceutycznej i Diagnostyki Molekularnej z Pracownią Diagnostyki Molekularnej i Farmakogenomiki, Międzywydziałowa Katedra Diagnostyki Laboratoryjnej i Molekularnej, Wydział Farmaceutyczny, Uniwersytet Medyczny w Łodzi

author

Marek Mirowski

• Zakład Biochemii Farmaceutycznej i Diagnostyki Molekularnej z Pracownią Diagnostyki Molekularnej i Farmakogenomiki, Międzywydziałowa Katedra Diagnostyki Laboratoryjnej i Molekularnej, Wydział Farmaceutyczny, Uniwersytet Medyczny w Łodzi

References

• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases regulators of the tumor microenviroment. Cell. 2010; 141: 52–67.
• Westermarck J, Veli–Matti K. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13: 781–792.
• Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011; 41: 271–290.
• Murphy G. Nagase H. Localising matrix metalloproteinase activities in the pericellular environment, FEBS J. 2011; 2–15.
• Kwiatkowski P, Godlewski J, Śliwińska–Jewsiewicka A, Kmieć Z. Rola metaloproteinaz macierzy zewnątrzkomórkowej w procesie inwazji nowotworu. Pol. Ann. Med. 2008; 15: 43–50.
• Lipka D, Boratyński J. Metaloproteinazy MMP. Struktura i funkcja, Post Hig Med Dośw. 2008; 62: 328–336.
• Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix Metalloproteinases and Cancer – Roles in Threat and Therapy. Asian Pac J Cancer Prev. 2014; 15: 1085–1091.
• Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med., 2011; 15: 1254–1265.
• Löffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance, Eur Respir J. 2011; 38: 191–208.
• Visse R, Nagase H. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Structure, Function, and Biochemistry. Circ Res. 2003; 92: 827–839.
• Shuman Moss LA, Jensen–Taubman S, Stetler–Stevenson WG. Changing Roles in Tumor Progression and Metastasis. Am J Pathol. 2012; 181: 1895–1899.
• Li DQ, Meller D, Liu Y, Tseng SGC. Overexpression of MMP–1 and MMP–3 by Cultured Conjunctivochalasis Fibroblasts. Invest Ophthalmol Vis Sci. 2000; 41: 404–410.
• Di Girolamo N, Tedla N, Lloyd A, Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur J Immunol. 1998; 28: 1773–1784.
• Melamed D, Messika O, Glass–Marmor L, Miller A. Modulation of matrix metalloproteinase–9 (MMP–9) secretion in B lymphopoiesis. Int Immunol. 2006; 18: 1355–1362.
• Farina AR, Mackay AR. Gelatinase B/MMP–9 in Tumour Pathogenesis and Progression. Cancers. 2014; 6: 240–296.
• Fink K, Boratyński J. Rola metaloproteinaz w modyfikacji macierzy zewnątrz–komórkowej w nowotworowym wzroście inwazyjnym, w przerzutowaniu i w angiogenezie Post Hig Med Dośw. 2012; 66: 609–628.
• Redondo–Muñoz J, Escobar–Díaz E, Samaniego R, Terol MJ, García–Marco JA, García–Pardo Á. MMP–9 in B–cell chronic lymphocytic leukemia is up–regulated by α4β1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 2006; 108: 3143–3151.
• Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K i wsp. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukemia. Br J Haematol. 2004; 125: 128–140.
• Deryugina E I, Quigley J P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim Biophys Acta. 2012;1803: 103–120.
• Czekierdowski A, Czekierdowska S, Daniłoś J, Rogala E, Nowicka A. Mimikra waskulogenna i ekspresja metaloproteinazy MMP–9 w guzach nowotworowych jajnika u kobiet. Przegląd menopauzalny. 2012; 2: 108–114.
• Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A i wsp. Increased serum levels of matrix metalloproteinase–9 predict clinical outcome of patients with early B–cell chronic lymphocytic leukaemia. Eur J Haematol. 2003; 70: 373–378.
• Nelson AM, Fingleton B, Rothenberg ML, Matrisian LM. Matrix Metallo–proteinases: Biologic Activity and Clinical Implications. J Clin Oncol. 2000; 18: 1135–1149.
• Hidalgo M, Eckhardt SG. Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. J Natl Cancer Inst. 2001; 93: 178–193.
• Roopali R, Jiang Y, Moses MA. Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer. J Clin Oncol. 2009; 27: 5287–5297.
• Zucker S, Cao J, Wen–Tien C. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancertreatment. Oncogene. 2000; 19: 6642–6650.
• Cathart J, Pulkoski–Gross A, Cao J. Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis. 2015; 1: 26–34.
• Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol. 2015; 44–46: 239–246.
• Kalva S, Azhagiya Singam ER2, Rajapandian V2, Saleena LM3, Subramanian V. Discovery of potent inhibitor for matrix metalloproteinase–9 by pharmacophore based modeling and dynamics simulation studies. J Mol Graph Model. 2014; 49: 25–37.

• Document Type: paper